A new artificial intelligence (AI) model predicted sudden cardiac death (SCD) risk more accurately than current clinical guidelines in people with cardiac sarcoidosis, according to a U.S. study. The AI model, called Multimodal Artificial Intelligence for Ventricular Arrhythmia Risk Stratification in Cardiac Sarcoidosis (MAARS-CS), estimates risk using heart MRI…

The Foundation for Sarcoidosis Research (FSR) has announced $400,000 in new funding to support early-stage research projects aimed at improving the diagnosis, treatment, and management of the rare inflammatory disease. The funding is divided into four grants of $100,000 each. Two were awarded to projects focused on cardiac…

Menopause is something that affects just about half of the population eventually. But for many, it remains a giant question mark, or a whole bunch of questions. In that way, it resembles sarcoidosis. There are the basic questions about it: Am I currently going through it? What stage am…

The Foundation for Sarcoidosis Research (FSR) has welcomed seven new institutions, including its first international member, into its FSR Global Sarcoidosis Clinic Alliance (FSR-GSCA), expanding a growing network of members dedicated to improving care for people living with sarcoidosis. Launched in 2022, the FSR-GSCA brings together leading…

Elevated levels of a blood protein called high-sensitivity cardiac troponin T (hs-cTnT) are associated with an increased risk of death and other adverse outcomes in people with cardiac sarcoidosis, and using a “simple, widely available blood test” measuring these levels to assess risk “could improve how we assess risk…

A mobile health app designed to guide breathing awareness meditation (BAM) sessions may effectively reduce fatigue and stress and improve the quality of life for people with sarcoidosis. That’s according to results from a pilot clinical trial (NCT05230693) that assessed the feasibility and efficacy of the Sarcoidosis Patient…

Sarcoidosis can significantly affect day-to-day life, and commonly used treatments may carry substantial risks of side effects, according to a report from the Foundation for Sarcoidosis Research (FSR). The report also finds that clinical trials testing new sarcoidosis treatments often do not fully reflect patient priorities, highlighting…

In people with cardiac sarcoidosis, patterns of signs and symptoms seen when the person is diagnosed can help predict the risk of long-term outcomes, including hospitalization and death, a new study shows. “The clinical phenotype [profile] of CS is a useful prognostic indicator,” researchers wrote, adding that these findings…

Among second-line treatments for sarcoidosis, methotrexate is safer and associated with a lower risk of hospitalization, intensive care, the need for breathing support, and death compared to mycophenolate mofetil (MMF), according to a large real-world study. Methotrexate also showed a trend toward better efficacy and similar safety…

It’s beginning to look a lot like chaos! It never fails — no matter how much we plan, the end of the year always seems to sneak up on us, bringing a rush of madness. There’s too much to do, and never enough time to do it. While that’s surely…